**Test Type:** RACB **Route:** Dosing in Feed

Species/Strain: Rat/Sprague-Dawley

C Number:

Study Gender:

**PWG Approval Date** 

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

**Test Compound:** 4-Methylimidazole **CAS Number:** 822-36-6

R92025B

Both

See web page for date of PWG Approval

Date Report Requested: 08/23/2018

Time Report Requested: 14:02:43

Lab: RTI

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

Species/Strain: Rat/Sprague-Dawley

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

# F0 Male

	Treatment Groups (ppm)			
	0	750	2500	5000
Disposition Summary				
Animals Initially In Study	23	23	23	23
Early Deaths				
Unscheduled Sacrifice			3	2
Survivors				
Scheduled sacrifice, terminal (SD 15 - 178)	23	23	20	21
Animals Examined Microscopically	23	23	23	23
ALIMENTARY SYSTEM				
LIVER	(23)	(0)	(23)	(23)
BASOPHILIC FOCUS			1 (4%)	
CLEAR CELL FOCUS			3 (13%)	
HEPATODIAPHRAGMATIC NODULE			1 (4%)	
PERIPORTAL; LYMPHOCYTE; INFILTRATION; FOCAL			2 (9%)	
INFLAMMATION, CHRONIC; ACTIVE, FOCAL			1 (4%)	
CENTRILOBULAR; NECROSIS; DIFFUSE			1 (4%)	
CENTRILOBULAR; NECROSIS; FOCAL			1 (4%)	
CENTRILOBULAR; HEPATOCYTE; VACUOLATION; CYTOPLASMIC				19 (83%)

CARDIOVASCULAR SYSTEM

No Tissues/Organs Examined

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole **CAS Number:** 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

-	N/1-	ı .
-11	Ma	ю

	Treatment Groups (ppm)			
	0	750	2500	5000
ENDOCRINE SYSTEM				
ADRENAL GLANDS	(23)	(0)	(23)	(23)
CORTEX; HYPERTROPHY; FOCAL				3 (13%)
CORTEX; BILATERAL; VACUOLATION; DIFFUSE	3 (13%)		3 (13%)	
CORTEX; VACUOLATION; FOCAL	1 (4%)		1 (4%)	5 (22%)
PITUITARY GLAND	(23)	(0)	(23)	(23)
PARS DISTALIS; CYST				1 (4%)
THYROID GLANDS	(23)	(0)	(23)	(23)
C-CELL; HYPERPLASIA; FOCAL	1 (4%)			

GENERAL BODY SYSTEM

No Tissues/Organs Examined

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

# F0 Male

	Treatment Groups (ppm)			
_	0	750	2500	5000
GENITAL SYSTEM				
COAGULATING GLANDS	(23)	(0)	(23)	(23)
COWPERS GLANDS	(23)	(0)	(20)	(21)
UNILATERAL; ATROPHY	1 (4%)			
EPIDIDYMIS	(22)	(23)	(23)	(23)
DUCT; RIGHT; EXFOLIATED GERM CELL			1 (4%)	
DUCT; EXFOLIATED GERM CELL	1 (5%)		2 (9%)	7 (30%)
DUCT; EXFOLIATED GERM CELL (TOTAL)	1 (5%)		3 (13%)	7 (30%)
HYPOSPERMIA			1 (4%)	
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(23)	(0)	(20)	(21)
PREPUTIAL GLANDS	(9)	(6)	(1)	(4)
UNILATERAL; ABSCESS	1 (11%)			
DUCT; ECTASIA	5 (56%)	5 (83%)	1 (100%)	4 (100%)
INFILTRATION; MONONUCLEAR CELL	1 (11%)			
INFLAMMATION		1 (17%)		
UNILATERAL; INFLAMMATION, CHRONIC; ACTIVE	1 (11%)			
INFLAMMATION, CHRONIC; ACTIVE	6 (67%)	5 (83%)		2 (50%)
INFLAMMATION, CHRONIC; ACTIVE (TOTAL)	7 (78%)	5 (83%)		2 (50%)
PROSTATE	(23)	(23)	(23)	(23)
VENTRAL LOBE; ATROPHY		9 (39%)	20 (87%)	23 (100%)
VENTRAL LOBE, INTERSTITIUM; LYMPHOCYTE; INFILTRATION	5 (22%)	5 (22%)	1 (4%)	
VENTRAL LOBE; INFLAMMATION; CHRONIC ACTIVE		1 (4%)		
SEMINAL VESICLES	(23)	(0)	(23)	(23)
TESTIS	(22)	(23)	(23)	(23)
GERMINAL EPITHELIUM; ATROPHY				1 (4%)
GERM CELL; DEGENERATION	1 (5%)		4 (17%)	8 (35%)
SEMINIFEROUS TUBULE; BILATERAL; SPERMATID RETENTION				1 (4%)
SEMINIFEROUS TUBULE; SPERMATID RETENTION	2 (9%)	3 (13%)	1 (4%)	7 (30%)

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

	N/1-1-

	F0 Male					
	Treatment Groups (ppm)					
	0	750	2500	5000		
SEMINIFEROUS TUBULE; SPERMATID RETENTION (TOTAL)	2 (9%)	3 (13%)	1 (4%)	8 (35%)		
HEMATOPOIETIC SYSTEM THYMUS	(23)	(0)	(23)	(23)		
NTEGUMENTARY SYSTEM  No Tissues/Organs Examined						
LYMPHOID SYSTEM  No Tissues/Organs Examined						
MUSCULOSKELETAL SYSTEM  No Tissues/Organs Examined						
NERVOUS SYSTEM  No Tissues/Organs Examined						
RESPIRATORY SYSTEM  No Tissues/Organs Examined						
SPECIAL SENSES SYSTEM  No Tissues/Organs Examined						
JRINARY SYSTEM						
KIDNEYS	(23)	(0)	(23)	(23)		
PELVIS; CONCRETION; FOCAL	00 (000()		1 (4%)	00 (000)		
NEPHROPATHY, CHRONIC PROGRESSIVE	22 (96%)		19 (83%)	22 (96%)		

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

# F0 Female

	Treatment Groups (ppm)			
	0	750	2500	5000
Disposition Summary				
Animals Initially In Study	23	23	23	23
Early Deaths				
Euthanized, moribund	1	1	3	8
Found Dead			1	1
Unscheduled Sacrifice				2
Survivors				
Scheduled sacrifice, terminal (LD 4, SD 28 - 220)	22	22	19	12
Animals Examined Microscopically	23	10	23	23
ALIMENTARY SYSTEM				
LIVER	(23)	(3)	(23)	(23)
ATROPHY; DIFFUSE				2 (9%)
CONGESTION; DIFFUSE	1 (4%)			1 (4%)
DEFORMITY		1 (33%)		
HEMATOPOIESIS; EXTRAMEDULLARY, FOCAL			1 (4%)	2 (9%)
HEPATODIAPHRAGMATIC NODULE		1 (33%)		
PERIPORTAL; LYMPHOCYTE; INFILTRATION; FOCAL	2 (9%)		1 (4%)	2 (9%)
CENTRILOBULAR; NECROSIS; DIFFUSE				1 (4%)
CENTRILOBULAR; NECROSIS; FOCAL			1 (4%)	

No Tissues/Organs Examined

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

	Treatment Groups (ppm)			
	0	750	2500	5000
ENDOCRINE SYSTEM				
ADRENAL GLANDS	(23)	(1)	(23)	(23)
CONGESTION; DIFFUSE			1 (4%)	
CORTEX; HYPERTROPHY; FOCAL				2 (9%)
CORTEX; VACUOLATION; FOCAL	3 (13%)			3 (13%)
PITUITARY GLAND	(23)	(1)	(23)	(23)
PARS DISTALIS; CYST				2 (9%)
THYROID GLANDS	(23)	(1)	(23)	(23)
C-CELL; HYPERPLASIA; FOCAL				3 (13%)
GENERAL BODY SYSTEM				
WHOLE BODY	(0)	(0)	(0)	(1)

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

**CAS Number:** 822-36-6

Time Report Requested: 14:02:43 Lab: RTI

Date Report Requested: 08/23/2018

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

	Treatment Groups (ppm)			
	0	750	2500	5000
GENITAL SYSTEM				
CERVIX	(23)	(1)	(23)	(21)
INFLAMMATION; ACUTE			1 (4%)	
CLITORAL GLANDS	(3)	(4)	(1)	(1)
UNILATERAL; ABSCESS; CHRONIC			1 (100%)	
DUCT; UNILATERAL; ECTASIA	1 (33%)	3 (75%)		
DUCT; ECTASIA	1 (33%)	1 (25%)		1 (100%)
DUCT; ECTASIA (TOTAL)	2 (67%)	4 (100%)		1 (100%)
INFILTRATION; MONONUCLEAR CELL	1 (33%)			1 (100%)
DUCT; LUMEN; INFLAMMATION, ACUTE				1 (100%)
UNILATERAL; INFLAMMATION, CHRONIC; ACTIVE		2 (50%)		
INFLAMMATION, CHRONIC; ACTIVE		1 (25%)		
INFLAMMATION, CHRONIC; ACTIVE (TOTAL)		3 (75%)		
OVARIES	(23)	(1)	(23)	(23)
CONGESTION	1 (4%)			
CORPUS LUTEUM; CYST				2 (9%)
FOLLICLE; CYST				1 (4%)
PLACENTA	(0)	(0)	(1)	(5)
BILATERAL; EDEMA				1 (20%)
EDEMA; DIFFUSE				3 (60%)
EDEMA				1 (20%)
INFLAMMATION; ACUTE				1 (20%)
INFLAMMATION; SUPPURATIVE				1 (20%)
BILATERAL; NECROSIS; DIFFUSE				1 (20%)
NECROSIS; DIFFUSE				1 (20%)
NECROSIS				1 (20%)
UTERUS	(23)	(3)	(23)	(23)
ENDOMETRIUM; CYST				1 (4%)

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

	Treatment Groups (ppm)			
	0	750	2500	5000
OVIDUCT; CYST			1 (4%)	
HORN; LUMEN; DILATION			1 (4%)	
DILATION		1 (33%)		
DILATION (TOTAL)		1 (33%)	1 (4%)	
ENDOMETRIUM; HYPERPLASIA; CYSTIC	2 (9%)			4 (17%)
INFLAMMATION; CHRONIC-ACTIVE			1 (4%)	
INFLAMMATION; SUPPURATIVE				2 (9%)
ENDOMETRIUM; METAPLASIA; SQUAMOUS	2 (9%)			
ENDOMETRIUM; METAPLASIA; SQUAMOUS (TOTAL)	2 (9%)	1 (33%)		
METAPLASIA; SQUAMOUS		1 (33%)		
NECROSIS				1 (4%)
ULCER; MULTIFOCAL			1 (4%)	
VAGINA	(23)	(1)	(23)	(23)
CYST			1 (4%)	
SUBMUCOSA; LYMPHOCYTE; INFILTRATION; FOCAL	1 (4%)			
INFLAMMATION; ACUTE			1 (4%)	
MUCIFICATION	7 (30%)		5 (22%)	
ULCER; FOCAL		,	1 (4%)	
HEMATOPOIETIC SYSTEM				
LYMPH NODE, MEDIASTINAL	(3)	(0)	(0)	(0)
CONGESTION	1 (33%)			
THYMUS	(23)	(1)	(22)	(23)
CORTEX; DECREASED LYMPHOCYTE; DIFFUSE			2 (9%)	6 (26%)

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

# Species/Strain: Rat/Sprague-Dawley

	F0 Female			
	Treatment Groups (ppm)			
	0	750	2500	5000
INTEGUMENTARY SYSTEM				
MAMMARY GLANDS	(1)	(2)	(0)	(0)
INFILTRATION; BACTERIA	1 (100%)			
INFLAMMATION; SUPPURATIVE	1 (100%)			
SKIN	(2)	(0)	(1)	(0)
ALOPECIA			1 (100%)	
LYMPHOID SYSTEM				
No Tissues/Organs Examined				
MUSCULOSKELETAL SYSTEM				
BONE	(1)	(0)	(0)	(0)
INTERVERTEBRAL DISK; RUPTURE; FOCAL	1 (100%)			
LIMB	(2)	(1)	(2)	(0)
ALOPECIA		1 (100%)	1 (50%)	
EPIDERMIS; HYPERPLASIA; FOCAL		1 (100%)		
EPIDERMIS; PARAKERATOSIS; FOCAL		1 (100%)		
RIGHT; ULCER; DIFFUSE			1 (50%)	
NERVOUS SYSTEM				
BRAIN	(0)	(0)	(0)	(2)
RESPIRATORY SYSTEM				
NOSE	(0)	(0)	(1)	(0)
SUBCUTANEOUS; CYST			1 (100%)	
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

	Treatment Groups (ppm)			
	0	750	2500	5000
URINARY SYSTEM				
KIDNEYS	(23)	(1)	(23)	(23)
PELVIS; CONCRETION; FOCAL				1 (4%)
PAPILLA; COLLECTING DUCT; DILATION	1 (4%)			
INFLAMMATION, ACUTE; FOCAL				1 (4%)
MINERAL	1 (4%)		2 (9%)	1 (4%)
RENAL TUBULE; NECROSIS; ACUTE, MULTIFOCAL				3 (13%)
NEPHROPATHY, CHRONIC PROGRESSIVE	17 (74%)	1 (100%)	11 (48%)	11 (48%)

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

**Species/Strain:** Rat/Sprague-Dawley

# F1 Male: F1 NonParental Male

	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary			
Animals Initially In Study	49	56	20
Early Deaths			
Survivors			
Scheduled sacrifice, terminal (PND 91 - 93)	49	56	20
Animals Examined Microscopically	49	56	20
Total number litters	18	22	8
ALIMENTARY SYSTEM			
LIVER	(49)	(1)	(20)
DEFORMITY			1 (5%) [1]
HEMATOPOIETIC CELL PROLIFERATION; EXTRAMEDULLARY			1 (5%) [1]
HYPERTROPHY; HEPATOCELLULAR	3 (6%) [2]		
ACCESSORY LOBE; INFARCTION		1 (100%) [1]	
LYMPHOCYTE; INFILTRATION; MULTIFOCAL	1 (2%) [1]		
CARDIOVASCULAR SYSTEM			
No Tissues/Organs Examined			
ENDOCRINE SYSTEM			
ADRENAL GLANDS	(49)	(1)	(20)
ATROPHY; DIFFUSE		1 (100%) [1]	
CORTEX; HYPERTROPHY; FOCAL	2 (4%) [1]		
METAPLASIA; OSSEOUS			1 (5%) [1]
CORTEX; VACUOLATION; FOCAL	1 (2%) [1]		
PITUITARY GLAND	(49)	(0)	(20)
PARS DISTALIS; CYST	4 (8%) [3]		
THYROID GLANDS	(49)	(0)	(20)

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

# F1 Male: F1 NonParental Male

	Treatment Groups (ppm)		
	0	750	2500
GENERAL BODY SYSTEM			
No Tissues/Organs Examined			
GENITAL SYSTEM			
COAGULATING GLANDS	(49)	(0)	(20)
COWPERS GLANDS	(48)	(3)	(20)
EPIDIDYMIS	(49)	(56)	(20)
DUCT; EXFOLIATED GERM CELL	3 (6%) [2]	5 (9%) [4]	4 (20%) [4]
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(49)	(0)	(20)
PROSTATE	(49)	(56)	(20)
VENTRAL LOBE; ATROPHY	4 (8%) [3]	25 (45%) [17]	17 (85%) [7]
VENTRAL LOBE, INTERSTITIUM; LYMPHOCYTE; INFILTRATION	25 (51%) [13]	33 (59%) [18]	6 (30%) [5]
VENTRAL LOBE; INFLAMMATION; CHRONIC ACTIVE	1 (2%) [1]		
INFLAMMATION; CHRONIC ACTIVE	1 (2%) [1]		
SEMINAL VESICLES	(49)	(1)	(20)
ATROPHY	1 (2%) [1]	1 (100%) [1]	
RUPTURE		1 (100%) [1]	
TESTIS	(49)	(56)	(20)
GERM CELL; DEGENERATION	4 (8%) [3]	6 (11%) [4]	1 (5%) [1]
SEMINIFEROUS TUBULE; SPERMATID RETENTION		3 (5%) [2]	4 (20%) [3]
HEMATOPOIETIC SYSTEM			
THYMUS	(49)	(0)	(20)
INTEGUMENTARY SYSTEM			
SKIN	(1)	(1)	(1)
DERMIS; FIBROSIS; FOCAL	· · ·	1 (100%) [1]	( )
EPIDERMIS; HYPERPLASIA; FOCAL		1 (100%) [1]	
LYMPHOID SYSTEM			
No Tissues/Organs Examined			

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

# F1 Male: F1 NonParental Male

	Treatment Groups (ppm)		
	0	750	2500
MUSCULOSKELETAL SYSTEM			
LIMB	(5)	(1)	(0)
BONE; DEFORMITY	4 (80%) [4]	1 (100%) [1]	
NERVOUS SYSTEM			
No Tissues/Organs Examined			
RESPIRATORY SYSTEM			
LUNGS	(1)	(1)	(0)
CONGESTION; DIFFUSE		1 (100%) [1]	
SPECIAL SENSES SYSTEM			
No Tissues/Organs Examined			
URINARY SYSTEM			
KIDNEYS	(49)	(1)	(20)
PAPILLA; COLLECTING DUCT; DILATION			1 (5%) [1]
PELVIS; RIGHT; DILATION	7 (14%) [6]	1 (100%) [1]	3 (15%) [3]
TRANSITIONAL CELL; EPITHELIUM; HYPERPLASIA; FOCAL		1 (100%) [1]	
MINERAL			1 (5%) [1]
NEPHROPATHY, CHRONIC PROGRESSIVE	45 (92%) [17]	1 (100%) [1]	20 (100%) [8]

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Lab: RTI

Date Report Requested: 08/23/2018

Time Report Requested: 14:02:43

F1 Female: F1 NonParent Female

	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary			
Animals Initially In Study	47	58	27
Early Deaths			
Survivors			
Scheduled sacrifice, terminal (PND 91 - 93)	47	58	27
Animals Examined Microscopically	47	58	27
Total number litters	17	22	12
ALIMENTARY SYSTEM			
LIVER	(47)	(2)	(27)
HEPATODIAPHRAGMATIC NODULE	1 (2%) [1]	1 (50%) [1]	1 (4%) [1]
LYMPHOCYTE; INFILTRATION; MULTIFOCAL	5 (11%) [5]		
INFLAMMATION, CHRONIC; ACTIVE, FOCAL	1 (2%) [1]		
CARDIOVASCULAR SYSTEM			
No Tissues/Organs Examined			
ENDOCRINE SYSTEM			
ADRENAL GLANDS	(47)	(0)	(27)
PITUITARY GLAND	(47)	(0)	(27)
PARS DISTALIS; CYST	1 (2%) [1]		1 (4%) [1]
THYROID GLANDS	(47)	(0)	(25)
FOLLICULAR CELL; MINERAL			1 (4%) [1]
GENERAL BODY SYSTEM			
No Tissues/Organs Examined			

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Time Report Requested: 14:02:43

Lab: RTI

Date Report Requested: 08/23/2018

# F1 Female: F1 NonParent Female

		Treatment Groups (ppm)		
	0	750	2500	
GENITAL SYSTEM				
CERVIX	(47)	(0)	(26)	
ENDOMETRIUM; CYST	1 (2%) [1]			
OVARIES	(47)	(2)	(27)	
CORPUS LUTEUM; CYST	1 (2%) [1]		1 (4%) [1]	
FOLLICLE; UNILATERAL; CYST		1 (50%) [1]		
UTERUS	(47)	(2)	(27)	
OVIDUCT; CYST			1 (4%) [1]	
SUBSEROSA; CYST	4 (9%) [4]			
ENDOMETRIUM; HYPERPLASIA; CYSTIC	4 (9%) [4]			
VAGINA	(47)	(0)	(27)	
MUCIFICATION	5 (11%) [3]			
HEMATOPOIETIC SYSTEM				
LYMPH NODE	(1)	(0)	(0)	
NO MICROSCOPIC FINDING RECORDED	1 (100%) [1]			
LYMPH NODE, MEDIASTINAL	(1)	(0)	(1)	
CONGESTION			1 (100%) [1]	
DECREASED LYMPHOCYTE			1 (100%) [1]	
SPLEEN	(2)	(1)	(0)	
THYMUS	(47)	(0)	(27)	
INTEGUMENTARY SYSTEM				
MAMMARY GLANDS	(47)	(0)	(27)	
SKIN	(1)	(1)	(0)	
ALOPECIA; DIFFUSE	,	1 (100%) [1]	. ,	
NO MICROSCOPIC FINDING RECORDED		1 (100%) [1]		
LYMPHOID SYSTEM				
No Tissues/Organs Examined				

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

# F1 Female: F1 NonParent Female

		Treatment Groups (ppm)		
	0	750	2500	
MUSCULOSKELETAL SYSTEM				
LIMB	(4)	(4)	(1)	
BONE; DEFORMITY	3 (75%) [3]	4 (100%) [3]	1 (100%) [1]	
PAW	(1)	(0)	(0)	
NO MICROSCOPIC FINDING RECORDED	1 (100%) [1]			
NERVOUS SYSTEM				
No Tissues/Organs Examined				
RESPIRATORY SYSTEM				
No Tissues/Organs Examined				
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				
URINARY SYSTEM				
KIDNEYS	(47)	(58)	(27)	
MINERAL	9 (19%) [7]	44 (76%) [19]	20 (74%) [11]	
NEPHROPATHY, CHRONIC PROGRESSIVE	27 (57%) [14]		21 (78%) [12]	

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

F1 Male: F1 Parental Males

	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary			
Animals Initially In Study	40	44	40
Early Deaths			
Euthanized, moribund			1
Survivors			
Scheduled sacrifice, terminal (PND 218 - 224)	40	44	39
Animals Examined Microscopically	40	44	40
Total number litters	18	22	15
ALIMENTARY SYSTEM			
LIVER	(40)	(0)	(40)
CLEAR CELL FOCUS	1 (3%) [1]		4 (10%) [3]
HEPATODIAPHRAGMATIC NODULE	3 (8%) [3]		5 (13%) [4]
BILE DUCT; HYPERPLASIA; FOCAL	1 (3%) [1]		1 (3%) [1]
HYPERTROPHY; DIFFUSE, HEPATOCELLULAR			1 (3%) [1]
LYMPHOCYTE; PERIPORTAL; INFILTRATION; MULTIFOCAL	1 (3%) [1]		7 (18%) [6]
INFLAMMATION, CHRONIC; ACTIVE, FOCAL	3 (8%) [3]		
HEPATOCYTE; NECROSIS; FOCAL	1 (3%) [1]		2 (5%) [2]
HEPATOCYTE; CENTRILOBULAR; VACUOLATION; CYTOPLASMIC, DIFFUSE			1 (3%) [1]
HEPATOCYTE; VACUOLATION; CYTOPLASMIC, FOCAL			1 (3%) [1]

No Tissues/Organs Examined

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

# F1 Male: F1 Parental Males

		Treatment Groups (ppm)		
	0	750	2500	
ENDOCRINE SYSTEM				
ADRENAL GLANDS	(40)	(0)	(40)	
CORTEX; HYPERTROPHY; FOCAL	1 (3%) [1]		1 (3%) [1]	
CORTEX; VACUOLATION; FOCAL			3 (8%) [3]	
CORTEX; VACUOLATION, CYTOPLASMIC; DIFFUSE	1 (3%) [1]		1 (3%) [1]	
PITUITARY GLAND	(40)	(0)	(40)	
PARS DISTALIS; CYST	3 (8%) [3]		1 (3%) [1]	
THYROID GLANDS	(40)	(0)	(40)	
C-CELL; HYPERPLASIA; FOCAL	1 (3%) [1]		1 (3%) [1]	
GENERAL BODY SYSTEM				
FAT	(2)	(0)	(0)	

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole **CAS Number:** 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

F1 Male: F1 Parental Males

	Treatment Groups (ppm)		
	0	750	2500
GENITAL SYSTEM			
COAGULATING GLANDS	(40)	(0)	(40)
COWPERS GLANDS	(40)	(0)	(40)
EPIDIDYMIS	(40)	(44)	(40)
DUCT; LEFT; EXFOLIATED GERM CELL			1 (3%) [1]
DUCT; RIGHT; EXFOLIATED GERM CELL			2 (5%) [2]
DUCT; EXFOLIATED GERM CELL		5 (11%) [5]	1 (3%) [1]
DUCT; EXFOLIATED GERM CELL (TOTAL)		5 (11%) [5]	4 (10%) [4]
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(40)	(0)	(40)
PREPUTIAL GLANDS	(3)	(1)	(0)
DUCT; UNILATERAL; ABSCESS	1 (33%) [1]		
UNILATERAL; INFLAMMATION, CHRONIC; ACTIVE	, , <del>,                                </del>	1 (100%) [1]	
PROSTATE	(40)	(44)	(40)
DORSAL LOBE; EPITHELIUM; ATROPHY			1 (3%) [1]
VENTRAL LOBE; ATROPHY	4 (10%) [3]	10 (23%) [8]	35 (88%) [15]
VENTRAL LOBE, INTERSTITIUM; LYMPHOCYTE; INFILTRATION	5 (13%) [4]	1 (2%) [1]	, , , -
SEMINAL VESICLES	(40)	(1)	(40)
ATROPHY			2 (5%) [2]
TESTIS	(40)	(44)	(40)
GERMINAL EPITHELIUM; LEFT; ATROPHY	1 (3%) [1]		1 (3%) [1]
GERMINAL EPITHELIUM; ATROPHY			1 (3%) [1]
GERMINAL EPITHELIUM; ATROPHY (TOTAL)	1 (3%) [1]		2 (5%) [2]
GERM CELL; LEFT; DEGENERATION	1 (3%) [1]		1 (3%) [1]
GERM CELL; DEGENERATION	1 (3%) [1]	5 (11%) [5]	4 (10%) [4]
GERM CELL; DEGENERATION (TOTAL)	2 (5%) [2]	5 (11%) [5]	5 (13%) [4]
SEMINIFEROUS TUBULE; SPERMATID RETENTION		5 (11%) [5]	4 (10%) [3]

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

# F1 Male: F1 Parental Males

	Treatment Groups (ppm)		
	0	750	2500
HEMATOPOIETIC SYSTEM			
LYMPH NODE, MEDIASTINAL	(1)	(0)	(0)
LYMPH NODE, RENAL	(1)	(0)	(0)
SPLEEN	(3)	(0)	(1)
HEMATOPOIETIC CELL PROLIFERATION; EXTRAMEDULLARY			1 (100%) [1]
PIGMENTED MACROPHAGE; INCREASED NUMBER; DIFFUSE	1 (33%) [1]		
THYMUS	(40)	(0)	(40)
INTEGUMENTARY SYSTEM			
SKIN	(0)	(2)	(0)
SKIN, ABDOMINAL	(3)	(0)	(0)
LYMPHOID SYSTEM			
No Tissues/Organs Examined			
MUSCULOSKELETAL SYSTEM			
DIAPHRAGM	(0)	(0)	(1)
LIMB	(1)	(0)	(1)
BONE; DEFORMITY	1 (100%) [1]	. ,	. ,
NERVOUS SYSTEM			
No Tissues/Organs Examined			
RESPIRATORY SYSTEM			
No Tissues/Organs Examined			
SPECIAL SENSES SYSTEM			
No Tissues/Organs Examined			

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

# F1 Male: F1 Parental Males

	Treatment Groups (ppm)		
	0	750	2500
JRINARY SYSTEM			
KIDNEYS	(40)	(6)	(40)
PELVIS; CONCRETION; FOCAL	6 (15%) [5]		1 (3%) [1]
PAPILLA; CYST			1 (3%) [1]
PELVIS; LEFT; DILATION	1 (3%) [1]		
PELVIS; RIGHT; DILATION	8 (20%) [7]	4 (67%) [3]	1 (3%) [1]
PELVIS; DILATION (TOTAL)	9 (23%) [8]	4 (67%) [3]	1 (3%) [1]
EPITHELIUM; TRANSITIONAL CELL; HYPERPLASIA; FOCAL (TOTAL)	5 (13%) [4]	1 (17%) [1]	1 (3%) [1]
EPITHELIUM; TRANSITIONAL CELL; HYPERPLASIA; FOCAL, LEFT	1 (3%) [1]		
EPITHELIUM; TRANSITIONAL CELL; HYPERPLASIA; FOCAL, RIGHT	4 (10%) [3]	1 (17%) [1]	1 (3%) [1]
TRANSITIONAL CELL; EPITHELIUM; INFLAMMATION, CHRONIC; ACTIVE, FOCAL	2 (5%) [2]	1 (17%) [1]	
MINERAL	3 (8%) [3]		5 (13%) [2]
NEPHROPATHY, CHRONIC PROGRESSIVE	40 (100%) [18]	6 (100%) [4]	40 (100%) [15]

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence
Test Compound: 4-Methylimidazole

**Test Type:** RACB **Route:** Dosing in Feed

Species/Strain: Rat/Sprague-Dawley

CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary			
Animals Initially In Study	40	44	40
Early Deaths			
Euthanized, moribund	2	3	6
Found Dead		1	1
Unscheduled Sacrifice	1	1	1
Survivors			
Scheduled sacrifice, terminal (LD 26 - 28, PND 246 - 251)	37	39	32
Animals Examined Microscopically	40	43	40
Total number litters	19	22	15
LIMENTARY SYSTEM			
LIVER	(40)	(43)	(40)
SUBCAPSULAR; FIBROSIS; FOCAL		1 (2%) [1]	
SUBCAPSULAR; HEMORRHAGE; FOCAL		1 (2%) [1]	
HEPATODIAPHRAGMATIC NODULE	1 (3%) [1]	1 (2%) [1]	2 (5%) [2]
BILE DUCT; HYPERPLASIA; DIFFUSE			1 (3%) [1]
LYMPHOCYTE; PERIPORTAL; INFILTRATION; MULTIFOCAL	9 (23%) [9]	6 (14%) [6]	5 (13%) [3]
INFLAMMATION, CHRONIC; ACTIVE, FOCAL	1 (3%) [1]		2 (5%) [2]
CENTRILOBULAR; NECROSIS; FOCAL			2 (5%) [2]
			1 (3%) [1]

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence
Test Compound: 4-Methylimidazole

Test Type: RACB
Route: Dosing in Feed

**CAS Number:** 822-36-6

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

# F1 Female: F1 Parental Females

	Treatment Groups (ppm)		
	0	750	2500
ENDOCRINE SYSTEM			
ADRENAL GLANDS	(40)	(43)	(40)
CORTEX; HYPERTROPHY; FOCAL	1 (3%) [1]		1 (3%) [1]
LYMPHOCYTE; INFILTRATION; MULTIFOCAL	1 (3%) [1]		
CORTEX; VACUOLATION; FOCAL		2 (5%) [2]	1 (3%) [1]
PITUITARY GLAND	(39)	(43)	(40)
PARS DISTALIS; CYST		1 (2%) [1]	
THYROID GLANDS	(40)	(43)	(40)
C-CELL; HYPERPLASIA; FOCAL	5 (13%) [5]	3 (7%) [3]	1 (3%) [1]
INFLAMMATION; CHRONIC ACTIVE	1 (3%) [1]		

GENERAL BODY SYSTEM

No Tissues/Organs Examined

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

**Experiment Number: R92025B** 

Test Type: RACB

Route: Dosing in Feed

	Treatment Groups (ppm)		
	0	750	2500
GENITAL SYSTEM			
CERVIX	(40)	(42)	(40)
SEROSA; CYST	1 (3%) [1]		
CLITORAL GLANDS	(3)	(0)	(0)
DUCT; UNILATERAL; ECTASIA	1 (33%) [1]		
DUCT; ECTASIA	2 (67%) [2]		
DUCT; ECTASIA (TOTAL)	3 (100%) [3]		
OVARIES	(40)	(43)	(40)
CORPUS LUTEUM; CYST; MULTIPLE			1 (3%) [1]
CORPUS LUTEUM; CYST		2 (5%) [2]	3 (8%) [3]
FOLLICLE; CYST		4 (9%) [4]	
CYST	1 (3%) [1]		
CORPUS LUTEUM; CYST (TOTAL)		2 (5%) [2]	4 (10%) [4]
PLACENTA	(0)	(1)	(0)
INFLAMMATION, ACUTE; MULTIFOCAL		1 (100%) [1]	
NECROSIS; MULTIFOCAL		1 (100%) [1]	
UTERUS	(40)	(43)	(40)
OVIDUCT; CYST			1 (3%) [1]
SUBSEROSA; CYST	1 (3%) [1]	2 (5%) [2]	2 (5%) [2]
HORN; DECIDUAL ALTERATION		1 (2%) [1]	
ENDOMETRIUM; HYPERPLASIA; CYSTIC	6 (15%) [4]		
ENDOMETRIUM; INFLAMMATION; SUPPURATIVE			1 (3%) [1]
ENDOMETRIUM; ULCER; FOCAL			1 (3%) [1]
VAGINA	(40)	(43)	(40)
MUCIFICATION	3 (8%) [3]		

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

	Treatment Groups (ppm)		
	0	750	2500
HEMATOPOIETIC SYSTEM			
LYMPH NODE, MEDIASTINAL	(1)	(1)	(0)
CONGESTION	1 (100%) [1]	1 (100%) [1]	
LYMPH NODE, MESENTERIC	(0)	(1)	(0)
SPLEEN	(0)	(1)	(0)
THYMUS	(40)	(42)	(40)
CORTEX; DECREASED LYMPHOCYTE; DIFFUSE	8 (20%) [7]	10 (24%) [9]	9 (23%) [8]
INTEGUMENTARY SYSTEM			
MAMMARY GLANDS	(40)	(43)	(40)
INFLAMMATION; SUPPURATIVE	· ,	, ,	1 (3%) [1]
INFLAMMATION, ACUTE; FOCAL		1 (2%) [1]	( / 1 1
LACTATION	1 (3%) [1]	( ), [ ]	
NECROSIS; FOCAL	( / 1	1 (2%) [1]	
SKIN	(1)	(2)	(1)
ABSCESS	1 (100%) [1]	,	( )
ALOPECIA	( /1.	2 (100%) [2]	1 (100%) [1]
LYMPHOID SYSTEM			, , , , ,
No Tissues/Organs Examined			
MUSCULOSKELETAL SYSTEM			
LIMB	(15)	(2)	(1)
BONE; DEFORMITY	11 (73%) [7]	1 (50%) [1]	1 (100%) [1]
NO MICROSCOPIC FINDING RECORDED	1 (7%) [1]	1 (50%) [1]	( )[]
NERVOUS SYSTEM			
No Tissues/Organs Examined			
RESPIRATORY SYSTEM			
No Tissues/Organs Examined			

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

	Treatment Groups (ppm)		
	0	750	2500
SPECIAL SENSES SYSTEM No Tissues/Organs Examined			
URINARY SYSTEM			
KIDNEYS	(40)	(43)	(40)
PELVIS; CONCRETION; FOCAL	9 (23%) [8]	1 (2%) [1]	2 (5%) [2]
PAPILLA; CYST		1 (2%) [1]	
RENAL TUBULE; EPITHELIUM; HYPERPLASIA; FOCAL			1 (3%) [1]
MINERAL	8 (20%) [5]	21 (49%) [14]	27 (68%) [12]
NEPHROPATHY, CHRONIC PROGRESSIVE	34 (85%) [17]	41 (95%) [21]	40 (100%) [15]
URINARY BLADDER	(1)	(0)	(0)

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole

CAS Number: 822-36-6

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

# F2 Male

	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary			
Animals Initially In Study	107	132	69
Early Deaths			
Survivors		400	
Scheduled sacrifice, terminal (PND 28)	107 10	132	69
Animals Examined Microscopically		5	
Total number litters	7	4	
ALIMENTARY SYSTEM			
No Tissues/Organs Examined			
CARDIOVASCULAR SYSTEM			
No Tissues/Organs Examined			
ENDOCRINE SYSTEM			
No Tissues/Organs Examined			
GENERAL BODY SYSTEM			
No Tissues/Organs Examined			
GENITAL SYSTEM			
TESTIS	(4)	(1)	(0)
SEMINIFEROUS TUBULE; DEGENERATION	2 (50%) [1]	1 (100%) [1]	
HEMATOPOIETIC SYSTEM			
No Tissues/Organs Examined			
INTEGUMENTARY SYSTEM			
No Tissues/Organs Examined			
LYMPHOID SYSTEM			
No Tissues/Organs Examined			

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

Route: Dosing in Feed

Test Type: RACB

Species/Strain: Rat/Sprague-Dawley

	F2 Male		
	Treatment Groups (ppm)		
	0	750	2500
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined			
NERVOUS SYSTEM  No Tissues/Organs Examined			
RESPIRATORY SYSTEM  No Tissues/Organs Examined			
SPECIAL SENSES SYSTEM  No Tissues/Organs Examined			
URINARY SYSTEM			
KIDNEYS	(6)	(4)	(0)
RENAL TUBULE; BILATERAL; CYST	1 (17%) [1]		
PELVIS; LEFT; DILATION		1 (25%) [1]	
PELVIS; RIGHT; DILATION	4 (67%) [3]	3 (75%) [2]	
LEFT; INFLAMMATION, CHRONIC		1 (25%) [1]	

Test Type: RACB

Route: Dosing in Feed

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Species/Strain: Rat/Sprague-Dawley

Date Report Requested: 08/23/2018 Time Report Requested: 14:02:43

Lab: RTI

F2 Female			
	Treatment Groups (ppm)		
	0	750	2500
Disposition Summary Animals Initially In Study Early Deaths Survivors Scheduled sacrifice, terminal (PND 28) Animals Examined Microscopically	98 98	132 132	76 76
ALIMENTARY SYSTEM  No Tissues/Organs Examined			
CARDIOVASCULAR SYSTEM  No Tissues/Organs Examined			
ENDOCRINE SYSTEM  No Tissues/Organs Examined			
GENERAL BODY SYSTEM  No Tissues/Organs Examined			
GENITAL SYSTEM  No Tissues/Organs Examined			
HEMATOPOIETIC SYSTEM  No Tissues/Organs Examined			
INTEGUMENTARY SYSTEM  No Tissues/Organs Examined			
LYMPHOID SYSTEM  No Tissues/Organs Examined			
MUSCULOSKELETAL SYSTEM  No Tissues/Organs Examined			

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole CAS Number: 822-36-6

Date Report Requested: 08/23/2018
Time Report Requested: 14:02:43

Lab: RTI

Route: Dosing in Feed

Test Type: RACB

Species/Strain: Rat/Sprague-Dawley

F2 Female			
	Treatment Groups (ppm)		
	0	750	2500
NERVOUS SYSTEM No Tissues/Organs Examined			
RESPIRATORY SYSTEM No Tissues/Organs Examined			
SPECIAL SENSES SYSTEM  No Tissues/Organs Examined			
URINARY SYSTEM  No Tissues/Organs Examined			

Experiment Number: R92025B PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence

Test Compound: 4-Methylimidazole
CAS Number: 822-36-6

Time Report Requested: 14:02:43

Date Report Requested: 08/23/2018

Lab: RTI

Species/Strain: Rat/Sprague-Dawley

Test Type: RACB

Route: Dosing in Feed

#### **LEGEND**

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Number of litters shown in square brackets for F1 and F2 animals

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

\*\* END OF REPORT \*\*